Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°£¼¼Æ÷¾ÏÀÇ ¿¹ÈÄ ¹× Ä¡·á ¼ºÀû¿¡ °üÇÑ ¿¬±¸ A Clinical Study on the Prognosis of Hepatocellular Carcinoma in Relation to Therapeutic Modalities

´ëÇѼÒÈ­±âÇÐȸÁö 1998³â 32±Ç 6È£ p.757 ~ 772
¼Ò¼Ó »ó¼¼Á¤º¸
¾ö¼øÈ£ ·ùÈ£»ó/¹Ú¹Ì¶ó/ÀÌÀç¿ø/À̼ºÁØ/À̱¸/±è±¤Èñ/ÁøÀ±ÅÂ/ÀüÈÆÀç

Abstract

¿ä¾à
¸ñÀû : °£¼¼Æ÷¾Ï¿¡ ´ëÇÑ Áø´Ü ¹× Ä¡·áÀÇ ÇöȲÀ» ÆľÇÇÏ°í, °£¼¼Æ÷¾ÏÀÇ ¿¹ÈÄÀÎÀÚ¸¦ Àç±Ô¸íÇÏ
¸ç, ¿¹ÈÄÁö¼ö¿¡ ÀÇÇÑ º´±âºÐ·ù¹ý(PI stage ºÐ·ù¹ý)¿¡ µû¶ó Ä¡·á ¹æ¹ýµéÀ» ºñ±³, ºÐ¼®ÇÔÀ¸·Î
½á º¸´Ù È¿À²ÀûÀÎ Áø´Ü ¹× Ä¡·á ´ëÃ¥À» ¼ö¸³ÇÏ°íÀÚ ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : °£¼¼Æ÷¾Ï ȯÀÚ 487¸íÀ» ´ë»óÀ¸·Î ÈÄÇâÀû ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù. Ä¡·á ¹æ¹ýÀº
º¸Á¸Àû Ä¡·á(¹«Ä¡·á), ¼ö¼ú(OP), °£µ¿¸Æ»öÀü¼ú(TOCE), °£µ¿¸Æ»öÀü¼ú°ú ¿¡ÅºÀ» ÁÖÀÔ¿ä¹ý
(PEI)ÀÇ º´ÇÕ¿ä¹ý(CEI)ÀÇ 4°¡Áö·Î ºÐ·ùÇÏ¿´À¸¸ç, PI stage ºÐ·ù¹ý¿¡ µû¶ó ȯÀÚ¸¦ ¼¼ºÐÇÑ ÈÄ
Ä¡·á¹æ¹ýº°, º´±âº° »ýÁ¸À² ºñ±³¸¦ ½ÃÇàÇÏ¿´´Ù.
°á°ú : °£¼¼Æ÷¾ÏÀÇ ¿¹ÈÄÀÎÀÚ·Î Ä¡·á À¯¹«, ¹®¸ÆÁ¾¾çÇ÷Àü, TNM stage, º¹¼ö, bilirubin,
alkaline phosphatase, ½Äµµ¡¤À§ Á¤¸Æ·ù, ¼ºº°ÀÇ 8°¡Áö Àӻ󺯼ö°¡ À¯ÀÇÇÏ¿´´Ù. °£¼¼Æ÷¾Ï ȯ
ÀÚÀÇ 1³â »ýÁ¸À²Àº Àüü ȯÀÚ±º 33%, ¹«Ä¡·á±º 7%, ³»°úÀûÄ¡·á±º 40%, ¼ö¼ú±º 87%À̾ú´Ù.
PI stageº°·Î °¢ Ä¡·á ¹æ¹ýÀÇ »ýÁ¸À²À» ºñ±³ÇØ º¸¸é, PI stage I¿¡¼­ OP±º°ú CEI±ºÀº »óÈ£
°£¿¡ À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾úÀ¸³ª µÎ ±º ¸ðµÎ TOCE±º¿¡ ºñÇÏ¿© ³ôÀº »ýÁ¸À²À» º¸¿´°í, TOCE
±ºÀº ¹«Ä¡·á±º¿¡ ºñÇÏ¿© ³ôÀº »ýÁ¸À²À» º¸¿´´Ù. PI stage ¥±¿¡¼­ Ä¡·á±ºÀº ¹«Ä¡·á±º¿¡ ºñÇÏ
¿© »ýÁ¸À²ÀÇ Çâ»óÀ» º¸¿´À¸¸ç, Ä¡·á±º°£¿¡´Â CEI±ºÀÌ TOCE±ºº¸´Ù ³ôÀº »ýÁ¸À²À» º¸¿´À¸³ª
OP±º°ú CEI±º, OP±º°ú TOCE±º °£¿¡ À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù. PI stage ¥²¿¡¼­´Â TOCE¸¸
ÀÌ ÀϺΠȯÀÚ¿¡¼­ ½ÃÇàµÇ¾úÀ¸¸ç ¹«Ä¡·á±º¿¡ ºñÇÏ¿© À¯ÀÇÇÑ »ýÁ¸À²ÀÇ Çâ»óÀ» º¸¿´´Ù. À̵é
TOCE±º Áß 6°³¿ù ÀÌ»ó »ýÁ¸ÇÑ È¯ÀÚÀÇ ºñÀ²Àº Ç÷û ºô¸®·çºóÀÌ 1.5 mg/dL ÀÌÇÏÀÇ °æ¿ì
70%À̾ú°í, 1.5 mg/dL¸¦ ÃÊ°úÇÏ´Â °æ¿ì 21%À̾úÀ¸¸ç ÈÄÀÚÀÇ 75%¿¡¼­ Á¾¾çÀÇ ÃÖ´ë Àå°æÀÌ
5 cm ÀÌÇÏÀ̾ú´Ù.
°á·Ð : PI stage¹ýÀº À¯¿ëÇÑ Ä¡·á ¼±ÅñâÁØÀ» Á¦°øÇÑ °ÍÀ¸·Î »ç·áµÈ´Ù. Áï, PI stage I¿¡¼­
´Â ÀÏÂ÷ÀûÀ¸·Î ¼ö¼úÀ» ½ÃÇàÇÏ°í, ¼ö¼úÀÌ ºÒ°¡´ÉÇÒ °æ¿ì CEI¸¦ ¼±ÅÃÇÑ´Ù. PI stage ¥±¿¡¼­´Â
CEI¸¦ ÁÖÃàÀ¸·Î ÇÏ°í, CEI·Î´Â ±ÙÄ¡°¡ ºÒ°¡´ÉÇϳª ¼ö¼úÀû ±ÙÄ¡°¡ ¿¹»óµÇ´Â °æ¿ì¿¡ ÇÑÇÏ¿©
¼ö¼úÀ» ¼±ÅÃÇÑ´Ù. PI stage ¥²¿¡¼­´Â Ç÷û bilirubinÀÌ 1.5 mg/dL ÀÌ»óÀÇ È¯ÀÚ´Â ¿ì¼±ÀûÀ¸·Î
TOCE¸¦ ½Ç½ÃÇÏ°í, 1.5 mg/dL¸¦ ÃÊ°úÇϴ ȯÀÚ´Â Á¾±«ÀÇ ÃÖ´ë Àå°æÀÌ 5 cm ÀÌÇÏÀÇ °æ¿ì¿¡
ÇÑÇÏ¿© Ãʼ±ÅÃÀû TOCE¸¦ ½ÃÇàÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
#ÃÊ·Ï#
Background/Aims : Recent progress in both diagnostic and therapeutic technique of
hepatocellular carcinoma (HCC) appears to improve the prognosis. The purpose of this
study was to evaluate the prognosis of HCC in relation to treatment methods.
Methods : A new staging scheme (PI stage) based on the prognostic index was used.
A total of 487 patients with HCC were divided into 4 treatment groups; no treatment
(No Tx), transarterial oily chemoembolization (TOCE), combination of percutaneous
ethanol injection and TOCE (CEI), partial hepatectomy (OP).
Results : In PI stage I, the groups of CEI and OP showed similar survival rates, and
both prolonged survival compared with the group of TOCE. In PI stage ¥±, CEI gave a
better survival than TOCE, whereas OP could not improve survival rate, compared with
TOCE. In PI stage ¥², only TOCE was done in some patients and it prolonged survival,
particularly when serum bilirubin was 1.5 mg/dL or less.
Conclusions : In the PI stage ¥°, operation is recommended firstly, but if operation is
impossible, CEI could be selected. CEI may be chosen as the first treatment choice in PI
stage ¥±. In PI stage ¥², TOCE may be considered for patients whose serum bilirubin is
1.5 mg/dL or less.

Å°¿öµå

°£¼¼Æ÷¾Ï; Ä¡·á ¹æ¹ý; ¿¹ÈÄ; Hepatocellular carcinoma; Treatment; Prognosis;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

MEDLINE
KCI
KoreaMed
KAMS